Biotech shares have fallen to earth with a thud in 2021 after hovering final 12 months amid pleasure over the event of Covid-19 vaccines, dealing huge losses to some hedge funds.
The sector is being buffeted by considerations Congress will transfer to place a lid on drug pricing and a surfeit of early-stage biotech shares because the IPO market booms.